Michela Simone

Dr. Michela Simone

Discipline of Chemistry, School of Environmental and Life Sciences, University of Newcastle, Callaghan, NSW 2308, Australia
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AMAmie J. Moyes
Amie J. Moyes
RKRayomand S. Khambata
Rayomand S. Khambata
IVInmaculada Villar
Inmaculada Villar
KBKristen J. Bubb
Kristen J. Bubb
RBReshma S. Baliga
Reshma S. Baliga
AHAdrian Hobbs
Adrian Hobbs
The endothelium plays a fundamental role in maintaining vascular homeostasis by releasing factors that regulate local blood flow, systemic blood pressure, and the reactivity of leukocytes and platelets. Accordingly, endothelial dysfunction underpins many cardiovascular diseases, including hypertension, myocardial infarction, and stroke. Herein, we evaluated mice with endothelial-specific deletion of Nppc, which encodes C-type natriuretic peptide (CNP), and determined that this mediator is essential for multiple aspects of vascular regulation. Specifically, disruption of CNP leads to endothelial dysfunction, hypertension, atherogenesis, and aneurysm. Moreover, we identified natriuretic peptide receptor–C (NPR-C) as the cognate receptor that primarily underlies CNP-dependent vasoprotective functions and developed small-molecule NPR-C agonists to target this pathway. Administration of NPR-C agonists promotes a vasorelaxation of isolated resistance arteries and a reduction in blood pressure in wild-type animals that is diminished in mice lacking NPR-C. This work provides a mechanistic explanation for genome-wide association studies that have linked the NPR-C (Npr3) locus with hypertension by demonstrating the importance of CNP/NPR-C signaling in preserving vascular homoeostasis. Furthermore, these results suggest that the CNP/NPR-C pathway has potential as a disease-modifying therapeutic target for cardiovascular disorders.


1 September 2007 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
MRMartijn D.P. Risseeuw
Martijn D.P. Risseeuw
MOMark Overhand
Mark Overhand
GFGeorge W.J. Fleet
George W.J. Fleet
Michela SimoneMichela Simone
Michela Simone

9 June 2015 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
PCPeter J. Cossar
Peter J. Cossar
LHLacey Hizartzidis
Lacey Hizartzidis
Michela SimoneMichela Simone
Michela Simone
AMAdam Mccluskey
Adam Mccluskey
CGChristopher Gordon
Christopher Gordon
There has been an increasing body of evidence that flow hydrogenation enhances reduction outcomes across a wide range of synthetic transformations. Moreover flow reactors enhance laboratory safety with pyrophoric catalysts contained in sealed cartridges and hydrogen generated in situ from water. This mini-review focuses on recent applications of flow chemistry to mediate nitro, imine, nitrile, amide, azide, and azo reductions. Methodologies to effect de-aromatisation, hydrodehalogenation, in addition to olefin, alkyne, carbonyl, and benzyl reductions are also examined. Further, protocols to effect chemoselective reductions and enantioselective reductions are highlighted. Together these applications demonstrate the numerous advantages of performing hydrogenation under flow conditions which include enhanced reaction throughput, yields, simplified workup, and the potential applicability to multistep and cascade synthetic protocols.

1 February 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JWJustin Warne
Justin Warne
GPGareth Pryce
Gareth Pryce
JHJulia M. Hill
Julia M. Hill
XSXiao Shi
Xiao Shi
FLFelicia Lennerås
Felicia Lennerås
DSDavid Selwood
David Selwood
The mitochondrial permeability transition pore is a recognized drug target for neurodegenerative conditions such as multiple sclerosis and for ischemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, PPIF), is a positive regulator of the pore, and genetic down-regulation or knock-out improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off-target effects, immunosuppression, and toxicity. We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine. X-ray analysis was used to validate the design concept, and biological evaluation revealed selective cellular inhibition of CypD and the permeability transition pore with reduced cellular toxicity compared with cyclosporine. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis, JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use.

18 August 2013 in Amino Acids
Verified
Journal Article
Closed access
PDF file
MRMartijn Risseeuw
Martijn Risseeuw
MOMark Overhand
Mark Overhand
GFGeorge W. J. Fleet
George W. J. Fleet
Michela SimoneMichela Simone
Michela Simone